IMDX Insight Molecular Diagnostics Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$5.24

Period return

+0.30 (+6.07%)

Volume

291.4K

2026-06-05O $6.55 H $6.55 L $5.2 C $5.24MA5 $5.99MA20 $5.92MA60 $4.57MA120 $5.39

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 02. 18.LowBUY4 months ago
Lake Street: Buy
US analyst rating / recommendation change.
2025. 11. 11.LowBUY7 months ago
Needham: Buy
US analyst rating / recommendation change.
2025. 08. 18.LowBUY10 months ago
Needham: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $8.33 · 3 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 10.	After market close (AMC)	$-0.23	—	—	$437.5K	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.26	—	—	$2.14M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-2.36	—	—	$395K	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-1.32	—	—	$280K	Reported

Insight Molecular Diagnostics Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 02. 18.	Lake Street	—	Maintain	Buy → Buy	—	Lake Street: Buy
2025. 11. 11.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy
2025. 08. 18.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy
2025. 05. 22.	Lake Street	—	Maintain	Buy → Buy	—	Lake Street: Buy
2025. 05. 13.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy
2025. 04. 08.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy